Navigation Links
WuXi PharmaTech Announces Second Quarter 2008 Results
Date:8/13/2008

SHANGHAI, China, Aug. 13 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced its selected unaudited financial results for the second quarter ended June 30, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Highlights for Second Quarter 2008:

-- Total net revenues increased 134% to $70.8 million in the second

quarter 2008 from $30.2 million in the second quarter 2007.

-- Non-GAAP operating income increased 90% to $17.0 million in the second

quarter 2008 from $8.9 million in the second quarter 2007; second

quarter 2008 GAAP operating income was $7.7 million.

-- Non-GAAP net income increased 81% to $15.5 million in the second

quarter 2008 from $8.6 million in the second quarter 2007; second

quarter 2008 GAAP net income was $8.5 million.

-- Second quarter 2008 non-GAAP diluted earnings per ADS were $0.21,

compared to $0.13 in the second quarter 2007; second quarter 2008 GAAP

diluted earnings per ADS were $0.12.

Numbers presented on a non-GAAP basis exclude share-based compensation expenses, amortization of acquired intangible assets and deferred tax impact on acquired intangible assets. The non-GAAP measures are described below and reconciled to the corresponding GAAP measure in the section below titled "Use of Non-GAAP Financial Measures."

Commenting on the second quarter 2008 results, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi Pharm
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007
2. WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award
3. WuXi PharmaTech Announces Third Quarter 2007 Results
4. WestChina-Frontier PharmaTech Awarded Full AAALAC Accreditation
5. WuXi PharmaTech (NYSE: WX) Mourns the Tragic Loss of Its Independent Director Shawn Wang
6. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
7. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
8. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
9. Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars
10. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
11. WuXi PharmaTech 2007 Annual Report Available Online
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3ASTRO Gildas Club Chicago join to promote cancer survivorship 59515 1Biomedical Research Centre searches for immunological biomarkers 59513 1Biomedical Research Centre searches for immunological biomarkers 59513 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 1KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 3KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 4